We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE þ filgrastim (second consolidation) and HiDAC þ AMSA þ filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m 2 þ cytarabine 800 mg/m 2 þ etoposide 150 mg/m 2 days 1-3) followed by filgrastim 300-480 lg once daily s.c. from day 11 after start of chemotherapy. Only four patients reached 45 CD34þ cells/ll blood (B-CD34 þ ) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of X2.0 Â 10 6 CD34 þ cells/kg after 1-3 leukaphereses. Group B: 20 patients, aged 50 (29-67) years, received HiDAC þ AMSA (cytarabine 3 g/m 2 b.i.d. days 1, 3, 5 þ amsacrine 150 mg/m 2 q.d. days 2, 4) followed by filgrastim at a similar dose starting on day 7. A total of 18 patients reached B-CD34 þ 45/ll and underwent PBSC harvesting, starting on day 23 (14-29) and yielding 4.0 (0.9-21) Â 10 6 CD34 þ cells/kg. Of 20 patients, 17 (85%) reached the defined target of X2.0 Â 10 6 CD34 þ cells/kg after 1-3 leukaphereses. We conclude that HiDAC þ AMSA þ G-CSF -in contrast to mini-ICE þ G-CSF -is an efficient regimen for mobilising PBSC in patients with AML CR1.
tic stem cell mobilisation
In patients with AML, the role of autologous stem cell transplantation (ASCT) remains controversial. 1, 2 Results from some large trials indicate that consolidation with ABMT in patients with AML in CR1 reduces the risk of relapse as compared to conventional chemotherapy, although this does not translate into improved long-term survival 3, 4 Using G-CSF-mobilised PBSC autografts, instead of bone marrow, has not been shown advantageous in terms of decreasing the relapse rate. 5 However, PBSCT is associated with faster haematopoietic recovery and less infectious morbidity as compared to ABMT. [5] [6] [7] Consequently, according to our joint national treatment program, patients with newly diagnosed intermediate/high-risk AML, who are not candidates for alloSCT, may undergo autologous PBSCT as final consolidation therapy.
In AML, the optimal regimen for mobilising PBSC has not yet been defined. A significant number of patients with myeloid malignancies mobilise poorly in response to chemotherapy (CT) and G-CSF 8, 9 Apart from the dose and scheduling of G-CSF, 7 the intensity and type of CT regimen used may be important for the successful collection of PBSC. [10] [11] [12] Thus, priming with high-dose cytarabine (alone or in combination with anthracyclines), has been associated with efficient collection of PBSC in AML, 8, 13 whereas fludarabine-based regimens have been less successful. 11 Promising results have been reported using ICE (idarubicin þ cytarabine þ etoposide) or modified ICE ('mini-ICE') in combination with G-CSF for mobilisation in patients with advanced myeloid leukaemias including AML. 14, 15 In an attempt to find an efficient and practical mobilising regimen in AML CR1, we have studied the yield of PBSC following mobilisation with mini-ICE þ filgrastim (given as second consolidation) and HiDAC þ AMSA þ filgrastim (given as third consolidation), respectively, in two consecutive groups of patients receiving treatment according to a joint protocol. Successful mobilisation was defined as 'the collection of X2.0 Â 10 6 CD34 þ cells/kg b.w. with a maximum of three leukaphereres'. 
Material and methods

AML treatment protocol
Eligibility criteria
Patients receiving treatment according to our joint protocol (see above) and having achieved CR1 following one or two cycles of induction therapy were eligible for this study, provided they were either planned for autologous PBSCT (upfront or if relapse were to occur), or if a back-up graft was needed for an URDT. At inclusion, all patients had received one consolidation with HiDAC. The recruitment period was 1997-2001. Five university hospitals (Go¨teborg, Lund, Malmo¨, Umea˚, Uppsala) and one Central hospital (Sundsvall) participated in the trial. Patients provided informed consent prior to inclusion. The study was approved by the respective local Ethics Committees.
Mobilisation of PBSC
Group A. Patients were mobilised with mini-ICE followed by filgrastim (nonglycosylated G-CSF; Neupogen s , AM-GEN s ) at a dose of 300 (p60 kg b.w.) or 480 mg (460 kg b.w.) s.c. once daily. G-CSF was administered from day 11 after start of CT until completion of leukaphereses, but not later than day 28. Mini-ICE was given as second consolidation (see above) and after recovery from previous cycle of CT (ie HiDAC).
Having analysed the leukapheresis yields for 18 consecutive patients mobilised by mini-ICE þ G-CSF (group A), we decided (09/99) to change the protocol. Stem cell collection was to be performed after HiDAC þ AMSA with a slightly different G-CSF schedule as described below. The protocol change was approved by the respective Ethics Committes.
Group B. Patients received HiDAC þ AMSA followed by filgrastim using the same dose and schedule (see above), but starting on day 7 after start of CT. HiDAC þ AMSA was given as third consolidation and after recovery from mini-ICE.
Procedures for monitoring and stem cell collection, as described below, were the same in the two groups.
Blood stem cell collection
Post nadir, the WBC was analysed daily to identify regeneration (WBC X1.0 Â 10 9 /l), after which the number of CD34 þ cells in blood (B-CD34) was determined daily. In patients reaching B-CD34 45/ml, 1-3 standard 10-15 l leukaphereses were performed daily until the target yield of X2.0 Â 10 6 CD34 þ cells/kg b.w. was obtained. Further aphereses could be performed at the discretion of the investigator. The harvest products were freezed and cryoperserved in DMSO at À1961C using standard techniques. CD34 þ cells in blood and aphereses products were enumerated at the local laboratories by immunofluorescence staining and flow cytometry using standard techniques including the same gating strategy. 17 There is a good correlation between the number of CD34 þ cells infused and haematopoietic recovery, 18 and a threshold number of X2 Â 10 6 CD34 þ cells/kg b.w. has been found to ensure prompt autologous engraftment. 19 Consequently, 'successful mobilisation' was defined by the study protocol as the collection of X2.0 Â 10 6 CD34 þ cells/kg with a maximum of three leukaphereses. Clinical decisions regarding patients not reaching this target yield after one mobilisation session were up to the discretion of the investigator. Available options were remobilisation after next chemotherapy, bone marrow harvesting and no more attempts to harvest stem cells.
Statistics
Data are given as median and range if not otherwise indicated. Confidence intervals for the main efficacy variables were calculated for the comparison between the groups.
Results
Patients
A total of 38 consecutive patients at six different hospitals were included in the study between April 1997 and May 2001. All had de novo AML in CR1, who had received no CT prior to the diagnosis and were treated according to our joint AML protocol. The first 18 patients (group A) were mobilised with mini-ICE þ G-CSF. Of these, 12 had obtained CR1 following only one induction cycle with Ida þ C, whereas six had required a second induction with ACE. Reasons for stem cell harvesting were planned APBSCT in CR1 (n ¼ 15) or in relapse (n ¼ 1) or backup for URDT (n ¼ 2). The second group (group B) of 20 patients were mobilised with HiDAC þ AMSA þ G-CSF. In all, 16 out of these had obtained CR1 following one induction course with Ida þ C, whereas four had required a second induction cycle with ACE. Reasons for stem cell harvesting were scheduled APBSCT in CR1 (n ¼ 15) or relapse (n ¼ 4) or backup for URDT (n ¼ 1). Patient characteristics in the two groups are summarised in Table 1 . (Table 2 ). Only 4/18 patients reached B-CD34 45/ml and consequently underwent 1-3 leukaphereses, starting days 18-26. In two out of these four patients, the target harvest yield (X2.0 Â 10 6 CD34 þ /kg) was reached (Table 3) . Thus, 2/18 (11%) were successfully mobilised as defined by the protocol. Patients failing to mobilise a sufficient number of PBSC either underwent remobilisation following next CT cycle (n ¼ 4), bone marrow harvesting (n ¼ 7) or no further attempts to collect stem cells (n ¼ 5). Interestingly, three patients failing to mobilise after mini-ICE þ G-CSF were successfully remobilised following the next cycle of CT (ie HiDAC-AMSA) with G-CSF at the same dose from day þ 7.
Group B. Starting 2 days after HiDAC-AMSA (day 7), filgrastim was administered for 18 (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) days. Following 1-2 weeks of severe pancytopenia, leukocytes increased to 41.0 Â 10 9 /l on day 21 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , and 45.0 Â 10 9 /l on day 23 (14-29), respectively. Peak B-CD34 ((19 (2-262)m/l)) was observed on day 23 (17-31) ( Table 2) . Notably, 18/20 patients reached B-CD34 45/ml and therefore underwent 1 (1-4) leukaphereses, starting on day 23 (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . All except one of these patients reached the target harvest yield after 1-3 leukaphereses (Table 3) . Thus, 17/20 (85%) patients were successfully mobilised. None of the poor mobilisers (n ¼ 3) underwent any further attempts to collect stem cells.
Discussion
We have shown that consolidation CT with HiDAC-AMSA followed by filgrastim at dose of E6 mg/kg/day results in efficient mobilisation and collection of PBSC, as measured by the number of CD34 þ cells, in a large proportion (17/20) of patients with AML in CR1. Notably, although most patients in the HiDAC-AMSA þ filgrastim group mobilised satisfactorily, peak B-CD34 showed a large interindividual variation (2-262/ml). The results are consistent with those of other groups, reporting efficient mobilisation of PBSC in acute leukaemia following treatment with intermediate-or high-dose cytarabine (with or without etoposide) and G-CSF. 13, 20 Our study adds the information that cytarabine and amsacrine is an efficient combination with regards to PBSC mobilisation. Of practical importance, maximal mobilisation occurred median 23 (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) days after start of mobilisation chemotherapy, coinciding with increasing WBC and at a time when patients were still thrombocytopenic. Although expected in a group of patients with severely diseased bone marrow, the variability in the timing of the PBSC peak is somewhat impractical necessitating careful monitoring of B-CD34 þ in order to optimise the timing of leukapheresis. The fact that a small number of patients (3/20) mobilised poorly is not unexpected. Previous studies in patients with lymphoma and leukaemia, using different mobilisation protocols and varying definitions of 'poor mobilisation', show that 10-25% of all patients fail to mobilise a sufficient number of PBSC. 8, 13, 21 Disappointingly, only 2/18 patients mobilised satisfactorily following consolidation CT with mini-ICE þ filgrastim. Reason(s) for these inferior results are unclear. Obviously, Efficient mobilisation of PBSC with HiDAC-AMSA M Höglund et al being a nonrandomised study, the difference in outcome between the two consecutive groups could be due to other factors than the priming regimens used. Thus, poor mobilisation of PBSC has been associated with a number of mainly disease-and treatment-related factors such as previous CT (ie large number of CT cycles premobilisation), previous large-field radiotherapy, prior exposure to certain kinds of 'stem-cell toxic' CT (ie BCNU, melphalan, fludarabine), short interval from last CT to mobilisation, tumour infiltration of bone marrow and high age. 8, 11, 12, [22] [23] [24] Moreover, previously untreated cancer patients as well as healthy individuals show a 10-fold interindividual variation in peak levels of PBPC in response to G-CSF. 25 However, all our patients were de novo AML in CR1 having received neither CT nor large-field radiotherapy prior to the diagnosis. Furthermore, the two groups are comparable with respect to age, lapse of previous chemotherapymobilisation and premobilisation blood counts (WBC, PLT). In the mini-ICE group, a somewhat higher fraction of patients (33%) needed two induction courses to obtain CR as compared with the HiDAC-AMSA group (25%). On the other hand, most patients in the HIDAC-AMSA group had received one more CT cycle, including mini-ICE, prior to stem collection. Thus, we believe that the differences in outcome do reflect a true difference in efficacy between the two mobilisation regimens. The fact that three patients in group A, who failed to mobilise following mini-ICE þ filgrastim, were successfully harvested after the subsequent CT course with HiDAC-AMSA þ filgrastim filgrastim speaks in favour of this hypothesis.
The mobilisation protocols differ in two respects -the CT regimens and the time at which filgrastim was added (8 vs 2 days after chemotherapy). Mini-ICE and HiDAC-AMSA are both highly myelosuppressive and efficient antileukaemic regimens. In our study, we observed a similar rate of marrow recovery (data not shown). As for mini-ICE, consolidation with intermediate/ high-dose cytarabine7etoposide has been associated with adequate collection of PBSC in patients with AML. 13, 14, 20, 26 Thus, it is tempting to speculate that the idarubicine component may have had a negative impact on mobilisation. Indeed, certain chemotherapeutic drugs, such as fludarabine, have been reported to impair mobilisation of PBSC. 11 On the other hand and arguing against a negative role of idarubicine, several previous investigators have reported a high percentage of successful PBSC collections in AML patients following consolidation with combination CT including idarubicine or other anthracyclines ( þ G-CSF). 8, 14, 27, 28 The optimal scheduling of G-CSF, as combined with CT for mobilisation of PBSC, is not known and may depend on the CT regimen used. 12 In most protocols, G-CSF is started 1-2 days after CT and administered once daily until completion of leukapheresis. However, results from two nonrandomised studies of PBSC mobilisation (not including AML patients) suggest that the addition of G-CSF may be delayed until 5-8 days after chemotherapy. 29, 30 Notably, in the latter study, further delaying the addition of G-CSF to 15 day post CT did result in inferior mobilisation. Based on the experience from the Carella group and attempting to minimise the exposure and costs of G-CSF, we started filgrastim as late as 8 days after mini-ICE (ie day 11) in the first group of patients. 14, 15 However, due to the high proportion of poor mobilisers, we decided to add filgrastim already 2 days following HiDAC-AMSA (ie day 7) in the second cohort. We can only speculate whether postponing the addition of G-CSF after HiDAC-AMSA would result in comparable efficacy of mobilisation and, possibly, more predictable time of harvesting. Studies trying to explore this are underway.
In conclusion, we have shown that consolidation with HiDAC þ AMSA þ filgrastim (from day 7) -but not mini-ICE þ filgrastim (from day 11) -mobilises CD34 þ cells efficiently in most patients with in AML CR1. The optimal time for PBSC harvesting is 17-29 days from start of chemotherapy. Reasons for the inferior mobilisation after mini-ICE þ filgrastim are unknown, but may either be related to a negative impact of idarubicin on mobilisation or to the delayed addition of G-CSF.
